Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

LET'S CONNECT THE DOTS...SHALL WE?

The "pandemic" has created a unique business opportunity for IPIX. The world needs an effective-COVID therapeutic that the evidence suggest IPIX has. A B-COVID EUA could generate billions in sales within months. The best way for IPIX to "maximize" the value of our plpeline is for IPIX to have the financial wherewithal to conduct ALL phases of their clinical trials. A B-COVID EUA could provide the necessary cash very quickly and give IPIX the essential ingredient it must have to "maximize" pipeline value...financial independence.

An EUA FOR The Treatment of COVID-19 Is Worth billion$ of dollars. A phase 2 drug that was found to have little to no effect on COVID-19, REMDESIVIR, earned $2.7B in 2020,in the 9 months after being awarded an EUA on May 1, 2020. Remdesivir had 1Q-2021 sales of nearly $1.5B. 11 months after receiving an EUA, REMDESIVIR earned over $4B. There is STILL no FDA approved, EFFECTIVE-treatment for COVID-19.

Leo seems to have positioned B-COVID well in terms of meeting the EUA requirements for safety and efficacy. That Brilacidin is safe can now be verified by clinical data on roughly 570 clinical trial participants. Brilacidin's evidence of efficacy could include the "molecular screenings", "Selectivity Index 426" and the preclinical antiviral activity of Brilacidin that will be presented by Dr. Narayanan at the ASV 2021, July 19-23. Additional clinical-efficacy evidence should come aproximately 2 weeks later (early August) when B-COVID's P-2 study data is unblinded, topline results reported, after which the EUA application can be completed and submitted. IMO, IPIX could have a EUA for B-COVID not later than END-of-WEEK OF Labor Day 2021.

I don't think any of what I'm proposing, regarding B-COVID and an EUA, is lost on Leo. Even if Leo is planning a B-COVID EUA I don't believe it would be wise, nor would he be at liberty, to discuss it. Likewise, if Leo has been engaged in on-going talks with various manufacturing entities, he probably wouldn't talk about that either.

This golden opportunity for IPIX to make billion$, in months not years, is a "limited-time offer." The 'Coronavirus Treatment Acceleration Program' (CTAP) is a special FDA emergency program for possible coronavirus therapies. The program uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful and probably the reason B-COVID has a fast track designation. According to CTAP there are, as April 30, 2021, 450+ COVID clinical trials underway and I'm guessin' many of them are aiming for the lower EUA efficacy standards. When the COVID-EUA and/or approved COVID therapeutics markets become flooded the "GRAVY TRAIN" is over.
https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap

My concern is that Leo not squander the "opportunistic" EUA billion$ of the present for the "potential" pipeline billions of the not-so-near future.